SCHEMBL1255490

SCHEMBL1255490

O=c1c(-c2ccccc2)c(O)oc2ccc(O)c(O)c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.48
KMT2A Q03164 7/20 0.48
KDM4E B2RXH2 7/20 0.48
MAPT P10636 6/20 0.48
GAA P10253 3/20 0.48
RECQL P46063 3/20 0.48
POLB P06746 2/20 0.48
PKM P14618 2/20 0.48
HSP90AA1 P07900 1/20 0.48
MAOA P21397 4/20 0.46
MGAM O43451 2/20 0.46
SI P14410 2/20 0.46
MGAM2 Q2M2H8 1/20 0.46
CYP3A4 P08684 6/20 0.45
ALOX15 P16050 6/20 0.45
HSD17B10 Q99714 5/20 0.45
TP53 P04637 5/20 0.45
HPGD P15428 4/20 0.45
LMNA P02545 3/20 0.45
MAPK1 P28482 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676342 0.84 KMT2A (0.58) MEN1KMT2AKDM4EMAPTRECQL
SCHEMBL1607111 0.82 MEN1 (0.62) MEN1KMT2AKDM4EMAPTPKM
SCHEMBL31344371 0.82 MEN1 (0.62) MEN1KMT2AKDM4EMAPTPKM
SCHEMBL23459097 0.81 MAOA (0.56) MEN1KMT2AKDM4EMAPTGAA
SCHEMBL16827005 0.81 MGAM (0.51) MEN1KMT2AKDM4EMAPTGAA
SCHEMBL31344370 0.81 MGAM (0.51) MEN1KMT2AKDM4EMAPTGAA
SCHEMBL8580811 0.79 MAPT (0.46) MEN1KMT2AKDM4EMAPTGAA
SCHEMBL471861 0.79 MEN1 (0.71) MEN1KMT2AKDM4EMAPTGAA
SCHEMBL27322035 0.78 FLT3 (0.64) MEN1KMT2AKDM4EMAPTGAA
SCHEMBL10324199 0.77 MGAM (0.56) MEN1KMT2AKDM4EMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 813 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3699174-B1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2025-11-12 EP claimed
CN-119015393-A Collagen peptide composition for improving vascular elasticity and preparation method thereof 山东隆贝生物科技有限公司 2024-11-26 CN claimed
US-11850230-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same ILAB (KR) 2023-12-26 US claimed
US-20230099574-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2023-03-30 US claimed
CN-113908147-A Application of 7,8,4 '-trihydroxyisoflavone and anti-haze preparation containing 7,8, 4' -trihydroxyisoflavone 高雄医学大学 2022-01-11 CN claimed
CN-113512018-A Flavonoid compound and preparation method and application thereof 合肥工业大学 2021-10-19 CN claimed
CN-113475635-A Additive premix for relieving oxidative stress of sows 广东省农业科学院动物科学研究所 2021-10-08 CN claimed
CN-112136980-A Additive premix for improving sow production performance 广东省农业科学院动物科学研究所 2020-12-29 CN claimed
EP-3699174-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2020-08-26 EP claimed
CN-111574490-A Synthesis method of polyhydroxy isoflavone 中国人民解放军联勤保障部队第九〇四医院 2020-08-25 CN claimed
US-20040209825-A1 Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto LAHEY THOMAS P (US) 2004-10-21 US claimed
CN-1141092-C Composition for preventing and treating osteoporosis and cancer and decreasing blood fat and its application 郭兴华 2004-03-10 CN claimed
CN-1475488-A Fluoro isoflavone containing derivative, monufacturing method and its use 东华大学 2004-02-18 CN claimed
CN-1424030-A Medicines for preventing and treating retina and cornea blood vessel diseases UNIV NANJING MEDICAL (CN) 2003-06-18 CN claimed
WO-2002074278-A1 TOPICAL COMPOSITION CONTAINING AN ASSOCIATION OF AVOCADO FURANE LIPIDS AND ISOFLAVONES LABORATOIRES EXPANSCIENCE (FR) 2002-09-26 WO claimed
EP-1189897-A1 ISOFLAVONE METABOLITES G.J. Consultants Pty Ltd (AU) 2002-03-27 EP claimed
CN-1306434-A Composition for preventing and/or treating osteoporosis and pathologies resulting from menopausal syndrome SIGMA TAU HEALTHSCIENCE SPA (IT) 2001-08-01 CN claimed
CN-1304724-A Composition for preventing and treating osteoporosis and cancer and decreasing blood fat and its application GUO XINGHUA (CN) 2001-07-25 CN claimed
WO-2000066576-A1 ISOFLAVONE METABOLITES G.J. CONSULTANTS PTY LTD (AU) 2000-11-09 WO claimed
CN-1259130-A Preparation of isoflavones from leguminous plants NOVOGEN INC (US) 2000-07-05 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11850230-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same TNF, NFKBIA, TRAF6 MEN1 4570/4885KMT2A 4786/4885KDM4E 2226/4885
US-20230099574-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME TNF, NFKBIA, TRAF6 MEN1 4570/4885KMT2A 4786/4885KDM4E 2226/4885
US-20040209825-A1 Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto HLA-DRB1, NFATC1, CD4 MEN1 4047/4885KMT2A 3519/4885KDM4E 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.